Adult Immunization

More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

NYU Langone Rusk Rehabilitation medical director Steven Flanagan, MD, discusses the "second crisis" of the pandemic and the impact on primary care.

The American Academy of Physical Medicine and Rehabilitation is a leading voice in the campaign for a national plan to address long COVID.

ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Vaccine fatigue in the US, says Vanderbilt University's William Schaffner, MD, is plentiful for vaccines that are are good—but not perfect.

Let's call the next round of COVID-19 shots "updated vaccines," and help the public understand the true role of this vaccination, says NFID's Schaffner.

Vaccine hesitancy and actual refusal can wear on clinicians over time; family physician Gretchen LaSalle, MD, offers potential antidotes to the frustration.

Listening to patient concerns about vaccines and guiding them to factual sources for answers pays off, says family physician Gretchen LaSalle, MD.

Adult vaccine awareness in the US is historically low and complicated this year by booster fatigue and lots of catch-up, says family physician Gretchen LaSalle, MD.

Vaccine hesitancy didn't begin with COVID but family physician Gretchen LaSalle, MD, says the pandemic has changed the tone of the reluctance. She explains in this interview.

IAC president Kelly Moore, MD, MPH, has a long history of fighting flu and promoting vaccination. She talks about the influenza/COVID season to come and using the best tools we have.